Transaction DateRecipientSharesTypePriceValue
12th January 2021David P Hochman15,741Grant/award etc.$0.00
21st December 2020Sean F. Moran87,500Exercise of derivative$1.40$122,500.00
21st December 2020Sean F. Moran87,500Open or private sale$1.75$153,125.00
18th December 2020Sean F. Moran53,610Exercise of derivative$1.00$53,610.00
18th December 2020Sean F. Moran53,610Open or private sale$1.40$75,054.00
16th December 2020Sean F. Moran36,923Open or private sale$1.32$48,627.59
16th December 2020Sean F. Moran36,923Exercise of derivative$0.17$6,118.14
4th December 2020David P Hochman5,000Open or private purchase$0.99$4,965.00
11th November 2020Yuval Cohen4,240Open or private purchase$1.21$5,126.16
12th October 2020David P Hochman18,466Grant/award etc.$0.00
Corbus Pharmaceuticals Holdings
Corbus Pharmaceuticals Holdings logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. The company was founded on December 18, 2013.

Ticker: CRBP
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1595097
Employees: 141
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags